The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for modulating the agricultural production of ruminants. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of decreasing acidosis.

The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for modulating the agricultural production of ruminants. In particular aspects, the disclosure provides methods of increasing feed efficiency, and methods of decreasing acidosis.

The present disclosure provides technologies for modulating microbiome of mammalian subjects (e.g., human subjects). The present disclosure, among others, provides therapeutic compositions and methods of using the same, wherein the therapeutic compositions comprising an engineered population of therapeutic bacteria that (i) are non-pathogenic and commensal in a subject to be administered; and (ii) are resistant to one or more target bacteriophages. In some embodiments, such therapeutic compositions can be useful for treatment of subjects suffering from or susceptible to a microbiome-dysfunction-associated disease, disorder, or condition (e.g., inflammatory bowel disease).

Provided are methods for treatment of bladder cancer using compositions of modified Mycobacterium bovis Bacillus Calmette et Guerin (BCG). Also, provided are methods of treatment of non-muscle invasive bladder cancer by intra-bladder injection of these modified BCG compositions. Also, provided are methods of treatment of muscle-invasive bladder cancer by intra-tumor injection of these modified BCG compositions.

Provided are methods for treatment of bladder cancer using compositions of modified Mycobacterium bovis Bacillus Calmette et Guerin (BCG). Also, provided are methods of treatment of non-muscle invasive bladder cancer by intra-bladder injection of these modified BCG compositions. Also, provided are methods of treatment of muscle-invasive bladder cancer by intra-tumor injection of these modified BCG compositions.

Provided herein are compositions and methods for treating cancer, treating colitis associated with immune checkpoint inhibitor therapy, colonizing the microbiome, and/or restoring the microbiome, by administering compositions or food products to a subject.

Provided herein are compositions and methods for treating cancer, treating colitis associated with immune checkpoint inhibitor therapy, colonizing the microbiome, and/or restoring the microbiome, by administering compositions or food products to a subject.

Provided herein are compositions and methods for treating cancer, treating colitis associated with immune checkpoint inhibitor therapy, colonizing the microbiome, and/or restoring the microbiome, by administering compositions or food products to a subject.

Kits and methods for rescuing at least one neuropeptide in a subject are described herein, including identifying at least one neuropeptide and recombining a nucleic acid sequence of the neuropeptide to obtain a recombinant nucleic acid neuropeptide; cloning the recombinant nucleic acid neuropeptide into a plasmid to obtain a recombinant neuropeptide plasmid and transforming the recombinant neuropeptide plasmid into a bacterial cell to obtain a transformed neuropeptide bacterial feed; and feeding the bacterial feed to the subject thereby rescuing the neuropeptide in the subject.

Kits and methods for rescuing at least one neuropeptide in a subject are described herein, including identifying at least one neuropeptide and recombining a nucleic acid sequence of the neuropeptide to obtain a recombinant nucleic acid neuropeptide; cloning the recombinant nucleic acid neuropeptide into a plasmid to obtain a recombinant neuropeptide plasmid and transforming the recombinant neuropeptide plasmid into a bacterial cell to obtain a transformed neuropeptide bacterial feed; and feeding the bacterial feed to the subject thereby rescuing the neuropeptide in the subject.